Ductile and low melting point drugs exhibit challenging behaviour during both particle size reduction and spray drying as considerable amount of heat is involved in both processes. In this study, a systematic approach was employed to understand the preparation and in-vitro performance of respirable nanoparticle agglomerates by coupling wet milling and spray drying for ibuprofen, which is a drug with a low melting point and challenging mechanical properties. Wet milling in the presence of two stabilizers differing in their thermal properties and subsequent spray drying of the suspensions were employed after the addition of mannitol and/or leucine. The effects of the stabilizer type and the amounts of mannitol (matrix former) and leucine (dispersibility enhancer), on the yield of the process, the particle size, the redispersibility (i.e. reformation of nanoparticles upon rehydration) and the aerosolization (fine particle fraction, FPF%) of the nanoparticle agglomerates were evaluated using standard least squares model and a 2 3 full factorial design (3 factors at 2 levels plus four centre points). All factors investigated were found to have a significant effect on the yield of nanoparticle agglomerates (p<0.05). The size of the nanoparticle agglomerates was mainly dependent on the leucine to drug ratio and the type of stabilizer (p<0.05), while mannitol to drug ratio was the only significant factor affecting the redispersibility of the formulations (p<0.05). The FPF%, determined using a fast screening impactor, was found to be dependent on both the leucine and mannitol to drug ratio (p<0.05). This study demonstrates the successful preparation of respirable nanoparticle agglomerates of low melting point and ductile ibuprofen and the usefulness of the design of experiments as a tool to understand the impact of the formulation parameters on their fabrication and in-vitro performance.
Introduction 1 2
Nanocrystals are nanosized drug particles. Nanocrystals are typically produced in 3 the form of nanosuspensions, which are submicron, colloidal dispersions of 4 nanosized drug particles, stabilised by surfactants, polymers, or a mixture of both 5 [1] . Nanocrystals have been suggested as a beneficial formulation approach for 6
Class IIa drugs of the Biopharmaceutics Classification System (BCS), for which 7 the dissolution rate is the rate-limiting step of absorption [2] . Considering the 8 various nanosizing techniques (i.e. top-down and bottom-up), wet milling is a 9 reproducible, cost-effective and scalable way of preparing nanosuspensions with 10 a typical size ranging from 200-500 nm [3] . Wet milling is the technique for the 11 preparation of the majority of the nanosuspension-based pharmaceutical 12
formulations that are either on the market or currently under development [4, 5] . 13 
14
Solidification of the nanosuspensions has been explored to combine the 15 advantages of liquid nanosuspensions (i.e. enhanced dissolution and solubility) 16 with the benefits of solid formulations (i.e. stability, easier handling, enhanced 17 patient compliance) producing nanoparticle agglomerates suitable for oral and 18 pulmonary delivery. Spray drying is a single-step process for the conversion of a 19 liquid feed into a dried particulate form. It is a popular process from an industrial 20 perspective as it is more cost-and time-effective compared to freeze drying [6] . 21 Therefore, preparation of nanosuspensions by wet milling followed by 22 solidification, using spray drying, has been suggested as a formulation approach 23 for nanoparticle agglomerates with enhanced dissolution and aerosolization 24 efficiency [7] [8] [9] [10] . 25 
26
Spray drying is also a fundamental particle engineering technique for pulmonary 27 drug delivery due to its simplicity, adaptability and scalability. Spray drying is a 28 rapid solidification procedure and the obtained particles (at least from solution 29 feed) are usually amorphous. Amorphicity is regarded as a disadvantage for 30 respirable particles as it is associated with the danger of recrystallisation upon 31 storage, which may influence adversely the stability, dissolution, absorption and 32 aerosolisation efficiency of the product [11] . Moreover, during spray drying 33 nanocrystals are exposed to thermal stresses, which may cause irreversible 34 aggregation to the resultant formulations [12] . Irreversible aggregation is linked 35 with poor redispersibility of the nanoparticle agglomerates, which cannot reform 36 nanoparticles upon rehydration leading to the loss of the advantages of the 37 nanoformulations [12, 13] . 38 
39
Addition of generally recognised as safe (GRAS) excipients in the liquid feed 40 before spray drying is a common strategy to manipulate the properties and thus the 41 performance of the dry powders. Mannitol is a non-reducing sugar, which has been 42 approved by regulatory authorities for use in inhalable pharmaceutical products 43 [14] . In particular, mannitol exhibits excellent spray-drying properties as the size 44 and morphology of the particles can be modified by varying the process parameters 45 [15] . The crystallinity of the spray-dried mannitol and the non-hygroscopic nature 46 of this excipient are advantageous for the long-term stability of the dry powders 47 suspension through a 0.1 μm disposable syringe filter to avoid extensive 151 dissolution and was then shaken vigorously for 30 s by hand before being 152 transferred to disposable sizing cuvettes. The measuring parameters were: 153 dispersant refractive index of 1.338 and viscosity of dispersion medium 0.89 cP. 154
All measurements were performed in triplicate. 155
Preparation of nanoparticle agglomerates 156
The obtained nanosuspensions were solidified by spray drying immediately after 157 preparation. 10 mL of nanosuspension were diluted to 100 mL with an aqueous 158 solution of mannitol and/or leucine to obtain the proportions reported in Table 1 . 159
Spray drying was performed using a laboratory scale spray dryer (Mini B-290, 160
Buchi Labortechnik, Switzerland) fitted with a high performance cyclone. On the 161 basis of preliminary experiments, the following parameters were employed: inlet 162 temperature of 70 o C, outlet temperature of 50 ± 2 o C, feed rate of 5 mL min -1 and 163 atomizing gas flow rate of 0.5 L s -1 . The collected nanoparticle agglomerates were 164 weighed and stored in a desiccator over silica gel for subsequent testing. 165
Determination of yield 166
Yield was calculated as the ratio of the mass of the particles collected after spray 167 drying to the mass of solids (drug and excipients) introduced in the feed suspension. 168
The drug quantity used in the calculations was the amount weighed in the milling 169 pots before the wet-milling step. 170 171
Characterization of nanoparticle agglomerates 172

Particle size analysis 173
Particle size distributions of the nanoparticle agglomerates were determined by 174 laser diffraction using a HELOS/ BR laser diffractometer (Sympatec, Germany) 175 which was fitted with the micro-dosing unit ASPIROS and the dry disperser 176 RODOS. Samples were placed in the feeder and pressurized air at 4 bar was used 177 to disperse them in the measurement chamber, while the feeding velocity was kept 178 constant at 50 mm s -1 . An R2 lens detector (0.25-87.5 μm) and the particle size 179 distribution analysis software Windox 5 (Sympatec, Germany) were used. The 180 D10, D50 and D90 particle sizes (i.e. the size in microns at which 10%, 50% and 181 90% of the particles are smaller) were recorded. Measurements were carried out 182 in triplicate. 183 184
Scanning electron microscopy 185
The morphology of the starting materials and the nanoparticle agglomerates was 186 investigated using scanning electron microscopy (SEM). Samples were placed on 187 to double-sided electro-conductive adhesive tape, which was fixed onto an 188 aluminium stub and then sputter-coated with gold (10 nm thickness Redispersibility index (RDI%) was determined according to Yue et al. [13] : 226
. 227
where, z-average0 is the intensity-weighted mean particle diameter of the 228 nanosuspensions prior to spray drying measured by DLS and z-average is the 229 corresponding value of nanosuspension reconstituted from nanoparticle 230 agglomerates upon rehydration. For the measurement of redispersibility, around 231 100 mg of each spray-dried powder was added to a glass vial containing 10 mL of 232 an aqueous saturated IBU solution and it was shaken vigorously for 30s by hand 233 before being transferred to disposable sizing cuvettes. The saturated solution of 234 ibuprofen was prepared by filtration of a drug suspension through a 0.1 μm 235 disposable syringe filter in order to avoid extensive dissolution. A RDI value close 236 to 100% indicates that the spray-dried nanoparticle agglomerates exhibit complete 237 reconstitution after rehydration to particles of similar size as the primary 238 nanocrystals after nanomilling and before the solidification step. 239
In-vitro dissolution testing 240
The paddle method was applied by using USP apparatus type II (Pharma Test, for drug content determination. Each formulation was tested in triplicate. The fine 274 particle fraction (FPF%) of the formulations was the ratio of the drug mass 275 depositing on the fine fraction collector divided by the recovered dose. The fine 276 particle dose (FPD) was calculated as the total mass deposited on the fine fraction 277 collector divided by the number of doses (n=3). 278 279
Design of Experiments 280
A full factorial design 2 3 (3 factors at 2 levels) was used allowing the estimation 281 of the main effects and the two-way interactions. The three independent variables 282 used at two levels in the design were: type of stabilizer (X1), mannitol to drug ratio 283 (X2) and leucine to drug ratio (X3). Dependent variables: yield, volume median 284 diameter (D50), redispersibility index (RDI%) and fine particle fraction (FPF%), 285
were selected as responses ( Table 1 ). The design matrix included 8 runs plus four 286 centre points (Fig. 1 ). Centre points were added to the design space to identify any 287 non-linearity in the responses. The design space was constructed and analyzed 288 using the JMP 12. 
Preparation and characterization of nanosuspensions 298
Both stabilizers were able to produce nanosuspensions of ibuprofen after 180 min 299 of wet milling. The results of z-average size and polydispersity index (PI) of 300 nanosuspensions obtained with both stabilizers as a function of milling time are 301 presented in (Fig. 2) . More specifically, after 180 min nanosuspensions stabilized 302 with HPMC and TPGS exhibited a z-average size of 533 ± 28 nm and 663 ± 12 303 nm, respectively. 304
305
The starting material, with a volume mean diameter D4,3: 64.5 ± 8.3 μm (Fig. 3)  306 initially showed rapid size reduction during milling, especially with HPMC as 307 stabilizer. In the case of HPMC, submicron particles of ibuprofen were produced 308 in 60 min while for TPGS this occurred in 90 min. The breakage rate of crystals 309 was high initially and with further milling time the size continued to decrease, but 310 at a slower rate for both stabilizers. This is a common profile as breakage rate 311 kinetics have been found to follow a first-order exponential decay [35] . 312
313
In the study of Nihei et al. [27] , thymoquinone, a low melting compound (m.p. 46 314 o C) with antioxidant properties had to be nanosized using a cold wet-milling 315 system in order to avoid the formation of large aggregates that were caused by the 316 partial melting of the compound when a wet mill without a heat exchanger was 317 used. In this study, no aggregation of ibuprofen was observed during milling 318 indicating that cautious selection of the process parameters (i.e. a lower milling 319 speed and an increased milling time with intervals so as to cool down the vessels) 320 could allow the use of wet mills which are not equipped with temperature control 321 accessories for the nano-comminution of low melting drugs. This could be 322 especially applicable to preformulation research at preclinical and clinical studies 323 were limited resources are available (i.e. time, equipment, investment, compound). 324
325
The results reported in this study can be favorably compared with those obtained 326 by rapid expansion of supercritical solutions [36] and high pressure 327 homogenization [37] , as both methods could not produce ibuprofen crystals with 328 size in the submicrometre scale. 329
Comminution of ibuprofen in water using a Lena DM 100 nanoparticle production 331 machine, equipped with a heat exchanger and operating in the recirculation mode, 332 resulted in nanosuspensions with z-average size around 450 nm [38] . The smaller 333 size of nanocrystals reported may be attributed to the use of a combination of 334 polymers and surfactants as stabilizers, and this also indicates the scalability of 335 wet milling in industrial settings [39] . 336 337
Yield 338
The yield was selected as a response characterizing quantitatively the overall 339 productivity of the process. For the experimental conditions applied the yield 340 ranged from 27.3% to 72.5% (Table 1 ). The generated model was significant and 341 the response was modeled with high accuracy (adjusted R 2 : 0.96, Table 2 ). 342
343
All the three independent variables were identified as significant with a positive 344 effect on the yield of the process (p<0.05, Table 2 ). The positive effect of 345 increasing the leucine and mannitol to drug ratios may be attributed to the 346 increased concentration of the solids dissolved in the feed suspension, prior to the 347 spray-drying step. Spray drying of nanosuspensions stabilized with TPGS led to 348 the lowest yield of 27.3%. This low yield may be attributed to the low melting 349 point of TPGS resulting in melting and adhesion of the nanoparticle agglomerates 350 to the drying chamber and cyclone. Replacing TPGS with HPMC, which is a non-351 thermolabile stabilizer increased the yield. The yield of the process was found to 352 maximize by increasing the leucine to drug ratio. This may be explained by the 353 fact that leucine accumulates on the surface of the particles forming a coating 354 around them and thus protecting them from high temperatures during spray drying. 355
Similar results were reported regarding the spray drying of hydro-alcoholic 356 solutions of β-estradiol where the powder yield increased with increasing leucine 357 content in the formulation [40] . The explanation proposed by the authors was that 358 when increasing leucine content was used, the drug was encapsulated in micelle-359 like structures of leucine and thus was protected from the relative harsh spray-360 drying conditions. 361
As shown in the surface plots (Fig. 6a,b) higher yields are obtained when HPMC 362 was used as the stabilizer of ibuprofen nanosuspensions, and when high leucine 363 and mannitol to drug ratios were used in the formulations prior to the spray-drying 364 step. 365 366
Characterization of nanoparticle agglomerates 367
Particle size and morphology 368
The SEM images of the formulations prepared based on the full factorial design 369 are shown in Fig. 4 (Table 1 and Fig.4,5) . 373
374
Addition of mannitol and/or leucine resulted in the promotion of spherical particles 375 with mean size approximately 2-3 μm that is suitable for pulmonary drug delivery. 376
The surface of the spray-dried particles appears not to be smooth and a closer 377 inspection reveals the presence of nanoparticles indicating the composite structure 378 of the particles where ibuprofen nanocrystals are embedded in a matrix of mannitol 379 and/or leucine (i.e. nanoparticle agglomerates). 380
381
The nanoparticle agglomerates containing leucine consist of individual particles 382 (e.g. patterns 1-+, 2-+, Fig.4,5 ). This may be attributed to the accumulation of 383 leucine at the surface of the particles preventing any particle fusion. A high leucine 384 to drug ratio resulted in wrinkled particles (patterns 1++, 2++, Fig.4,5) . A wrinkled 385 morphology was interpreted as an indication of hollow particles as the particle 386 density was found to decrease as the "wrinkleness" of the particles was increased 387 [41] . 388
389
The nanoparticle agglomerates appear to be porous with holes and dimples in the 390 particle surface due to the evaporation of liquid that escapes from the inner of the 391 droplet through the solid crust built up in the course of the drying process on the 392 surface of the droplet [15, 42] . Engineering of porous particles is considered 393 beneficial for pulmonary drug delivery as particles with high porosity have smaller 394
aerodynamic diameter compared to non-porous particles of the same physical size, 395 increasing the probability for deposition in the lower respiratory tract [43] . 396
397
The particle size of the nanoparticle agglomerates obtained was measured by laser 398 diffraction as a volume diameter ( Table 1 ). The dried powders obtained exhibited 399 a median diameter D50 between 2.15 and 16.04 μm and the data are in good 400 agreement with the particle size observed by SEM. The results were analyzed in 401 the experimental design performing ANOVA for particle size, focusing on the D50 402 value and the model was found significant (p<0.05, Table 2 ). 403
404
Leucine to drug ratio and the type of stabilizer used were identified as formulation 405 variables with the most significant effects on the D50 (Table 2) . Their "negative" 406 effect is interpreted as size reduction, which is desirable for pulmonary drug 407 delivery. The observation regarding the influence of leucine on particle size is in 408 agreement with the study of Sou et al. [20] in which it was reported that leucine in 409 contrast to glycine and alanine was the only amino acid that reduced the D50 when 410 added into the mannitol formulations. Also, it is likely that increased leucine to 411 drug ratio enhanced surface coating around the particles, which prevented the 412 particles from melting and sintering, as observed for the process yield. 413
414
A significant interaction was identified between leucine to drug ratio and the type 415 of stabilizer, with a positive parameter estimate, despite the fact that the factors 416 had individually negative effects on the D50 (Table 2) , indicating a synergistic 417 rather than an additive interaction between HPMC and leucine to drug ratio. Use 418 of the non-melting HPMC as a nanosuspension stabilizer and the addition of a high 419 leucine to drug ratio leads to further particle size reduction than the individual 420 factors alone. 421
As shown in the surface plot, spray drying of ibuprofen nanosuspensions stabilized 422 with HPMC and containing a high leucine to drug ratio is able to produce 423 nanoparticle agglomerates with particle size around 2-3 μm that is suitable for 424 pulmonary drug delivery (Fig. 6c) . On the other hand, spray drying of ibuprofen 425 nanosuspensions stabilized with TPGS results in larger particles, while addition of 426 both high leucine and mannitol to drug ratios was required in order to produce 427 particles smaller than 4 μm (Fig. 6d) . This indicates that the selection of stabilizer 428 is vital not only for the step of nanosuspension production, but it may also 429 influence the downstream process of spray drying by affecting the properties of 430 the nanoparticle agglomerates produced. 431
Redispersibility 432
Redispersibility is an important quality attribute of nanoparticle agglomerates as 433 it is a prerequisite for the reformation of nanoparticles upon rehydration of the 434 larger particles with potential enhancement of therapeutic efficacy. Particularly, 435 for nanoparticles of low melting drugs such as ibuprofen, thermal stresses during 436 spray drying may lead to phase and composition changes of formulations causing 437 irreversible aggregation and loss of the advantages of nanoformulations [12] . An 438 RDI% value close to 100% means that the nanoparticle agglomerates reformed 439 nanoparticles with z-average size close to the z-average size of the primary 440 nanoparticles prior to the solidification step. For the experimental conditions 441 applied, the redispersibility index (RDI%) ranged from 148 % to 938% (Table 1) . 442
The redispersibility results were analyzed in the experimental design performing 443 ANOVA for particle size focusing on the RDI% value and the model was found 444 significant (p<0.05, Table 2 ). 445
446
The mannitol to drug ratio was identified as the only significant factor affecting 447 redispersibility (p<0.05, Table 2 ) with higher mannitol to drug ratio leading to 448 RDI% values closer to 100%. The role of mannitol as a redispersibility enhancer 449 can be explained by the formation of a continuous matrix around the nanocrystals 450 during the spray-drying step, preventing their irreversible aggregation. Upon 451 rehydration, mannitol as a hydrophilic excipient dissolves and the 452 nanosuspensions are reconstituted. 453
454
As shown in the surface plots (Fig. 7a,b) , nanoparticle agglomerates of ibuprofen 455 with enhanced redispersibility (RDI% value close to 100%) were obtained only 456 when high mannitol to drug ratios are present in the formulations prior to the spray-457 drying step. 458
Drug loading 459
The results of assayed ibuprofen content in the nanoparticle agglomerates are 460 given in Table 3 . Spray drying of nanosuspensions without mannitol and/or leucine 461 appeared to have lower drug loading than the nominal. This may be attributed to 462 the melting of TPGS during spray drying that led to drug loss due to deposition on 463 the walls of the drying chamber and cyclone. For the spray-dried nanosuspensions 464 containing mannitol and/or L-leucine the assayed ibuprofen content is close to the 465 nominal content indicating that the addition of these excipients prevented 466 ibuprofen loss or powder segregation during the production process. 467 468
Solid state characterization 469
The XRPD patterns of the starting materials are shown in Fig.8a . Raw ibuprofen 470 exhibited sharp peaks in the range of 2 theta: [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] o that are characteristic of the 471 drug [38, 44] The diffractograms of all runs prepared according to the DoE are shown in indicating the absence of generated amorphous content during the process. 483
484
The DSC was used to assess the thermal behaviour of the starting materials and 485 nanoparticle agglomerates of ibuprofen (Fig. 9) . The DSC thermogram of 486 ibuprofen showed an endothermic peak at 76 o C corresponding to the melting of 487 the drug. The nanoparticle agglomerates of ibuprofen without mannitol and 488 leucine exhibited the same endothermic peak shifted to a slightly lower 489 temperature (Fig. 9a) , while those containing mannitol exhibited thermal 490 behaviour depending on the stabilizer. 491
492
More specifically, the nanoparticle agglomerates of ibuprofen containing mannitol 493 and stabilized with TPGS exhibited two endothermic peaks (patterns 2++, 2+-, 494 followed by crystallization to the α-or/and β-form, and the melting of the 503 respective crystal form [47] . Both α-and δ-form of mannitol were found to be 504 chemically and physically stable for at least 5 years when stored at 25 o C and 43% 505 relative humidity [47] . Recently, co-spray drying of an aqueous solution of 506 mannitol with PVP in a ratio 4:1 was reported to produce the δ-form of mannitol 507 [48] . 508 509 Overall, the XRPD and DSC data suggest that the engineered nanoparticle 510 agglomerates retain their crystallinity during wet bead milling followed by spray 511 drying. The preservation of the crystalline state is advantageous, ensuring the long-512 term physical stability of the formulations during storage. 513 514
Residual moisture content 515
Thermogravimetric analysis of the spray-dried powders indicated that the moisture 516 content of the powders ranged from 1.1 to 4.7% w/w (Table 3) . These values 517 compare favourably with other studies which report moisture content of spray-518 dried powders in the region of 5-10% w/w [49, 50] . Specifically, residual moisture 519 content ranged from 2.3 to 4.7% for the nanoparticle agglomerates stabilized with 520 HPMC and from 1.1 to 2.3% for those stabilized with TPGS and it was reduced 521 for the agglomerates with high mannitol to drug ratio (Table 3 ). This is in 522 agreement with the results reported by Yamasaki et al. [7] , that increasing mannitol 523 content in nanomatrix powders of ciclosporin A reduced the residual moisture 524 content of the formulations, which was attributed to its non-hygroscopic nature. minimize the moisture content of the nanoparticle agglomerates that is required 528 for quality reasons (e.g. physical and chemical stability, reduced cohesiveness 529 during storage, non-aggregation) [51] . 530
In-vitro dissolution tests 531
The dissolution profiles of ibuprofen and the nanoparticle agglomerates prepared 532 according to the matrix of the full factorial design are shown in Fig. 10 . 533
Nanoparticle agglomerates stabilized with either HPMC or TPGS exhibited 534 enhanced dissolution profiles compared to ibuprofen. In the case of the raw 535 ibuprofen, less than 40% was released in the first 20 min, while the nanoparticle 536 agglomerates achieved complete dissolution in less than 5 min. The exceptions to 537 this were the spray-dried nanosuspensions of ibuprofen without matrix former 538 (patterns 1--and 2--) which exhibited a higher dissolution rate compared to 539 ibuprofen but slower than the nanoparticle agglomerates containing mannitol 540 and/or leucine. In the case of TPGS, this may be associated with the formation of 541 large aggregates with size around 50 μm and poor redispersibility (Fig. 5) . Thus, 542 the selection of suitable process and formulation parameters is of paramount 543 importance in order to ensure that the dissolution benefit of nanoparticles is 544 retained after spray drying. 545 546
In-vitro aerosol performance 547
Fine particle fraction (FPF) was selected as a quality attribute describing the 548 aerodynamic performance of a dry powder for inhalation. The European 549 Pharmacopoeia (2.9.18 preparations for inhalation: aerodynamic assessment of 550 fine particles, Ph. Eur. 8.0) suggest that a pressure drop over the inhaler of 4 kPa 551 is broadly representative of the pressure drop generated by the patients using dry 552 powder inhalers during inhalation [52] . In this study, operating a 'medium' 553 resistance device as Cyclohaler® at 30 L min -1 leads to a low pressure drop across 554 the inhaler. While this low pressure drop across the inhaler reduces the probability 555 of establishing comparable in-vitro performance and in-vivo drug deposition, it is 556 considered acceptable for comparing the in-vitro aerosolisation performance of 557 formulations prepared in this study. The FPF values of the nanoparticle 558 agglomerates produced ranged from 5.84 to 68.55% (Table 1 ) and the model 559 generated was found to be significant (p<0.05, Table 2 ). 560
561
Leucine to drug ratio and mannitol to drug ratio were identified as the most 562 significant factors on the FPF (Table 2. ). The positive effect of leucine can be 563 linked with its properties as a dispersibility and aerosolization enhancer. In 564 contrast to other amino acids such as alanine and glycine, leucine has been found 565 to reduce capsule retention and increase both the emitted and the fine particle 566 fraction of formulations [20, 22] . For spray-dried particles of salbutamol sulfate 567 and lactose containing increasing amount of leucine (5-20% w/w), Seville et al 568 [22] observed an increase of the FPF% (from 50% to 80%, respectively). In 569 another study, Sou et al. [20] reported the highly significant and positive effect of 570 leucine on improving the FPF% of spray-dried mannitol particles. 571
573
Regarding the positive effect of mannitol to drug ratio, it may be attributed to the 574 good spray-drying properties of mannitol which facilitates the formation of 575 spherical particles with narrow and unimodal particle size distribution [15, 53] . 576
577
As illustrated in the surface plots (Fig. 7c, d ), both leucine and mannitol to drug 578 ratio have a significant effect on the aerodynamic performance of the nanoparticle 579 agglomerates, resulting in a large FPF increase from 10% to over 65%. Therefore, 580 a combination of high leucine and mannitol to drug ratios is required in order to 581 maximise the FPF of the nanoparticle agglomerates of the low melting and ductile 582 ibuprofen. 583 584
Conclusions 585
Nanosuspensions of the poorly water-soluble, low melting point and ductile drug 586 ibuprofen stabilized with HPMC and TPGS were successfully produced and were 587 further spray dried with or without the addition of excipients (mannitol and/or L-588 leucine) employing a full factorial design. Design of experiments is a useful 589 approach in order to gain insight into the formation of inhalable nanoparticle 590 agglomerates using wet milling followed by spray drying. Leucine to drug ratio, 591 mannitol to drug ratio and the type of stabilizer were found to be significant 592 (p<0.05) factors affecting the yield of the particles obtained by combining wet 593 milling and spray drying. The particle size response was mainly dependent on the 594 leucine to drug ratio and the type of stabilizer employed (p<0.05). Mannitol to 595 drug ratio was found to be the only critical parameter affecting redispersibility of 596 nanoparticle agglomerates (p<0.05), and both leucine to drug ratio and mannitol 597 to drug ratio were found to be significant factors affecting FPF (p<0.05). While 598 the importance of the type of stabilizer on the formation of nanosuspensions has 599 been previously reported [33, 54, 55] , in this study it was observed that the selection 600 of stabilizer could also influence the downstream process of spray drying by 601 affecting the yield and the particle size distribution of the resultant nanoparticle 602 agglomerates. Moreover, the nanoparticle agglomerates were found to be 603 crystalline which is advantageous for their physical stability upon storage, and they 604 exhibit enhanced dissolution compared to the ibuprofen starting material. Overall, 605 it appears that by selecting the stabilizer and adjusting the mannitol and leucine to 606 drug ratio during the spray drying of nanosuspensions can result in nanoparticle 607 agglomerates with enhanced dissolution and aerosolization behaviour despite the 608 challenging properties (thermal and mechanical) of a drug as ibuprofen. 609 Tables   Table 1 Matrix of full factorial design, yield of process and characteristics of spray-dried nanoparticle agglomerates: volume diameter, redispersibility (RDI %), fine particle fraction (FPF%) and fine particle dose (FPD).
Table 2
Summary of the regression analysis and ANOVA results. Table 3 Nominal content and assayed ibuprofen content (% w/w) of nanoparticle agglomerates together with calculated drug loading efficiency (%) and residual moisture content (mean ± SD, n=3). Table 1 Matrix of full factorial design, yield of process and characteristics of spray-dried nanoparticle agglomerates: volume diameter, redispersibility (RDI %), fine particle fraction (FPF%) and fine particle dose (FPD). Figure 1 The three-dimensional design space of the 2 3 full factorial design. 
